GE and Geron to work on embryonic stem cell assays
This article was originally published in Clinica
Executive Summary
GE Healthcare is to partner with pharmaceutical firm Geron in the development of cellular assays for use in drug discovery, drug development and toxicity screening. As part of an exclusive global alliance, scientists from the two companies will work on assay products derived from human embryonic stem cells (hESCs). GE will fund the research and development process for the assays, and will also be responsible for the manufacturing, sales and distribution of the resulting products. Financial terms of the deal were not disclosed. According to GE, the partnership with Geron is designed to improve early in vitro screening of drug candidates and, in turn, reduce both overall drug development costs and potentially harmful patient exposure during clinical trials.